{
    "eid": "2-s2.0-85119347300",
    "title": "Thromboembolic and hemorrhagic risks after vaccination against SARS-CoV-2: a systematic review and meta-analysis of randomized controlled trials",
    "cover-date": "2021-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Hemorrhage",
        "SARS-CoV-2",
        "Thromboembolism",
        "Vaccine"
    ],
    "authors": [
        "Noppacharn Uaprasert",
        "Krissana Panrong",
        "Ponlapat Rojnuckarin",
        "Thita Chiasakul"
    ],
    "citedby-count": 13,
    "ref-count": 32,
    "ref-list": [
        "Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review",
        "Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine",
        "Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine",
        "Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19",
        "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",
        "Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia",
        "Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",
        "Safety and efficacy of NVX-CoV2373 Covid-19 vaccine",
        "Covid-19 vaccination hesitancy",
        "US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, march 2 to April 21, 2021",
        "Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination",
        "Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination",
        "Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination",
        "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement",
        "RoB 2: a revised tool for assessing risk of bias in randomised trials",
        "A proposed framework to guide evidence synthesis practice for meta-analysis with zero-events studies",
        "Measuring in consistency in meta-analyses",
        "Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study",
        "Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study",
        "First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland",
        "Safety of the BNT162b2 mRNA Covid-19 vaccine in a Nationwide setting",
        "Systemic coagulopathy in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis",
        "COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection",
        "Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis",
        "Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis",
        "Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study",
        "Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations",
        "Thromboembolic events in the south African Ad26.COV2.S vaccine study"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60028190",
        "affilname": "Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
        "affiliation-country": "Thailand"
    },
    "funding": []
}